Upcoming events

First registry results from the newly approved ACURATE TA™ TAVI system

Selected in European Journal of Cardio-Thoracic Surgery by Rylski



Kempfert J, Holzhey D, Hofmann S, Girdauskas E, Treede H, Schröfel H, Thielmann M, Walther T


Eur J Cardiothorac Surg. 2015 Jul;48(1):137-41


July 2015


Read the article

My Comment


The authors reported on the first 250 patients who underwent transapical aortic valve implantation with the novel ACURATE TA™ system.


  • Multicenter report with 17 centers in 4 countries; 250 patients included.
  • Mean aortic gradient of 43.2 ± 17.4 mmHg, mean age of 80.9 ± 6.3 years, mean society of thoracic surgeons risk score of 8.0 ± 5.9% and mean logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) I of 22.3 ± 12.7%.
  • The technical success rate was of 98% with 2 valve-in-valve procedures and 3 conversions to conventional surgery.
  • The 30-day mortality rate was of 6.8%.
  • The relevant paravalvular leak (moderate 2+) was observed in 2.3%, all other had none/trace or a 1+ leak.
  • The 30-day stroke rate was 2.8%.
  • The pacemaker implantation was required in 10%.

My comments

ACURATE TA™ system is the third commercially available TAVI system in Europe since 2011. It comprises a self-expanding nitinol stent with a regular surgical porcine tissue valve. Nitinol stent is covered by an anti-paravalvular leak skirt. The results of this first post-market study are promising. Especially the very low rate of relevant paravalvular leak may improve the survival, since residual leak after TAVI is a well-known risk factor for mid-term mortality. It seems that the inner and outer skirts for sealing off paravalvular leak and the characteristic ‘pull-down’ manoeuvre during valve deployment, which leads to ‘capping’ the calcified leaflets within the stent, works well. The 30-day mortality rate compares well with other reports (FRANCE-2 9.7%, SENTINEL 7.4%). This novel TAVI system expands notably the armamentarium of transcatheter technics for treatment of aortic valve stenosis. Cardiac arrhythmia requiring pacemaker implantation is still an issue in TAVI technology.

No comments yet!